Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion

被引:30
作者
Chiara, S
Nobile, MT
Barzacchi, C
Sanguineti, O
Vincenti, M
DiSomma, C
Meszaros, P
Rosso, R
机构
[1] Oncologia Medica I, Inst. Naz. Per la Ricerca Sul Cancro, 16132 Genova
关键词
hand-foot syndrome; 5-fluorouracil; continuous infusion; colorectal cancer; METASTATIC COLORECTAL-CARCINOMA; FOLINIC ACID; LEUCOVORIN CALCIUM; 24-HOUR INFUSION; RANDOMIZED TRIAL; CANCER; FLUOROURACIL; ONCOLOGY; CHEMOTHERAPY; THERAPY;
D O I
10.1016/S0959-8049(96)00497-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy. 70 advanced colorectal cancer patients (pts) were given weekly 24 h continuous 5-FU (2600 mg/m(2)) infusion plus L-LV (100 mg/m(2) i.v., 50 mg orally). The toxicity, in particular HFS, was analysed, correlated to the main pts characteristics and compared to the other observed side-effects. HFS occurred in 36/70 pts (51%): grade 1 in 16 pts, grade 2 in 16 pts, grade 3 in 3 pts and grade 4 in 1 pt. It occurred after a median number of nine courses. In one case, chemotherapy was interrupted for this toxicity, and in another 5 pts drug reduction and/or treatment delay were undertaken. Changes in the therapeutic programme because of diarrhoea or mucositis were more frequent, even though these toxicities were generally mild in our series of pts. HFS was significantly correlated to previous exposure to chemotherapy (P = 0.00003). HFS was a frequent side-effect of high-dose, short-term continuous 5-FU infusion, but the impact on quality of life of pts and on the correct delivery of the planned chemotherapy was limited. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:967 / 969
页数:3
相关论文
共 16 条
[1]  
[Anonymous], 1992, J CLIN ONCOL
[2]   A PHASE-II STUDY OF WEEKLY 24-HOUR INFUSION WITH HIGH-DOSE FLUOROURACIL WITH LEUCOVORIN IN COLORECTAL-CARCINOMA [J].
ARDALAN, B ;
CHUA, L ;
TIAN, EM ;
REDDY, R ;
SRIDHAR, K ;
BENEDETTO, P ;
RICHMAN, S ;
LEGASPI, A ;
WALDMAN, S ;
MORRELL, L ;
FEUN, L ;
SAVARAJ, N ;
LIVINGSTONE, A .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :625-630
[3]   5-FLUOROURACIL AND FOLINIC ACID IN THE TREATMENT OF METASTATIC COLORECTAL-CANCER - A RANDOMIZED COMPARISON - A SOUTHWEST ONCOLOGY GROUP-STUDY [J].
BUDD, GT ;
FLEMING, TR ;
BUKOWSKI, RM ;
MCCRACKEN, JD ;
RIVKIN, SE ;
OBRYAN, RM ;
BALCERZAK, SP ;
MACDONALD, JS .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (02) :272-277
[4]   RANDOMIZED COMPARISON OF 2 SCHEDULES OF FLUOROURACIL AND LEUCOVORIN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER [J].
BUROKER, TR ;
OCONNELL, MJ ;
WIEAND, HS ;
KROOK, JE ;
GERSTNER, JB ;
MAILLIARD, JA ;
SCHAEFER, PL ;
LEVITT, R ;
KARDINAL, CG ;
GESME, DH .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) :14-20
[5]   WEEKLY HIGH-DOSE INFUSION OF 5-FLUOROURACIL IN ADVANCED COLORECTAL-CANCER [J].
DIAZRUBIO, E ;
ARANDA, E ;
MARTIN, M ;
GONZALEZMANCHA, R ;
GONZALEZLARRIBA, J ;
BARNETO, I .
EUROPEAN JOURNAL OF CANCER, 1990, 26 (06) :727-729
[6]   PROSPECTIVE RANDOMIZED COMPARISON OF FLUOROURACIL VERSUS FLUOROURACIL AND HIGH-DOSE CONTINUOUS INFUSION LEUCOVORIN CALCIUM FOR THE TREATMENT OF ADVANCED MEASURABLE COLORECTAL-CANCER IN PATIENTS PREVIOUSLY UNEXPOSED TO CHEMOTHERAPY [J].
DOROSHOW, JH ;
MULTHAUF, P ;
LEONG, L ;
MARGOLIN, K ;
LITCHFIELD, T ;
AKMAN, S ;
CARR, B ;
BERTRAND, M ;
GOLDBERG, D ;
BLAYNEY, D ;
ODUJINRIN, O ;
DELAP, R ;
SHUSTER, J ;
NEWMAN, E .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :491-501
[7]   A RANDOMIZED TRIAL OF FLUOROURACIL AND FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA [J].
ERLICHMAN, C ;
FINE, S ;
WONG, A ;
ELHAKIM, T .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) :469-475
[8]  
FABIAN CJ, 1990, INVEST NEW DRUG, V8, P57
[9]   TREATMENT OF ADVANCED-STAGE COLORECTAL ADENOCARCINOMA WITH FLUOROURACIL AND HIGH-DOSE LEUCOVORIN CALCIUM - A PILOT-STUDY [J].
HINES, JD ;
ZAKEM, MH ;
ADELSTEIN, DJ ;
RUSTUM, YM .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (01) :142-146
[10]  
HRYNIUK WM, 1987, SEMIN ONCOL, V14, P3